HCW Biologics Inc
HCWB8.810USD
-1.240-12.34%
Fechamento 05/14, 16:00（ET）Cotações atrasadas em 15 min
392.41MValor de mercado
PerdaP/L TTM
Mais detalhes de HCW Biologics Inc Empresa
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Informações da empresa
Código da empresaHCWB
Nome da EmpresaHCW Biologics Inc
Data de listagemJul 20, 2021
Fundado em2018
CEODr. Hing C. Wong, Ph.D.
Número de funcionários36
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 20
Endereço2929 N Commerce Pkwy
CidadeMIRAMAR
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33025
Telefone19548422024
Sitehttps://hcwbiologics.com/
Código da empresaHCWB
Data de listagemJul 20, 2021
Fundado em2018
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
493.86K
+23.05%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
12.08K
+80.41%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President of Business Development
Senior Vice President of Business Development
5.72K
+20.23%
Mr. Gary M. Winer
Mr. Gary M. Winer
Independent Director
Independent Director
2.73K
+543.06%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President of Clinical Operations
Chief Scientific Officer, Vice President of Clinical Operations
1.94K
+0.05%
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
+0.11%
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
493.86K
+23.05%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
12.08K
+80.41%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President of Business Development
Senior Vice President of Business Development
5.72K
+20.23%
Mr. Gary M. Winer
Mr. Gary M. Winer
Independent Director
Independent Director
2.73K
+543.06%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President of Clinical Operations
Chief Scientific Officer, Vice President of Clinical Operations
1.94K
+0.05%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: há 23 horas
Tempo de atualização: há 23 horas
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Wong (Hing C)
43.96%
Armistice Capital LLC
4.50%
Byam (Rebecca)
3.83%
Garrett (Scott T)
1.08%
Avantax Planning Partners, Inc
0.62%
Other
46.01%
Estatísticas dos acionistas
Acionista
Proporção
Wong (Hing C)
43.96%
Armistice Capital LLC
4.50%
Byam (Rebecca)
3.83%
Garrett (Scott T)
1.08%
Avantax Planning Partners, Inc
0.62%
Other
46.01%
Tipo
Acionista
Proporção
Individual Investor
50.05%
Hedge Fund
4.57%
Investment Advisor
1.54%
Investment Advisor/Hedge Fund
1.32%
Research Firm
0.03%
Other
42.48%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
37
530.40K
48.29%
+53.17K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
2023Q1
32
22.37M
62.46%
-3.36M
2022Q4
32
22.28M
62.20%
-3.33M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Wong (Hing C)
16.05M
35.73%
--
--
Nov 22, 2024
Armistice Capital LLC
2.02M
4.5%
+2.02M
--
Dec 31, 2024
Byam (Rebecca)
1.38M
3.08%
--
--
Apr 15, 2024
Garrett (Scott T)
267.86K
0.6%
+142.86K
+114.29%
Apr 15, 2024
Avantax Planning Partners, Inc
279.54K
0.62%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
37.68K
0.08%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
181.96K
0.4%
-1.30K
-0.71%
Dec 31, 2024
Flowers (Lee)
190.24K
0.42%
+71.43K
+60.12%
Feb 20, 2024
Cresset Asset Management, LLC
131.99K
0.29%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: ter, 6 de mai
Tempo de atualização: ter, 6 de mai
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados